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Abstract
Background: It is critical to understand the pattern of antiretroviral treatment (ART) prescription in different regions of the
world as ART procurement needs to be anticipated. We aimed at exploring rates and predictors of ART combination changes
in clinical practice in Treat Asia HIV Observational Database (TAHOD).
Methods: Rates of ART changes were examined in patients who started first line triple or more ART combination in TAHOD,
and had at least one follow-up visit. Rates of ART changes were summarised per follow-up year, and factors associated with
changes assessed using random-effect Poisson regression. The Kaplan-Meier method was used to determine durations of
patients in their first, second and third regimen.
Results: A total of 1846 patients initiated an ART combination with at least three drugs. Median follow up time for the first
treatment was 3.2 years. The overall rate of ART change was 29 per 100-person-year.
In univariate analyses, rate of treatment change was significantly associated with exposure category, the country income
category, the drug class combination, calendar year and the number of combinations. In multivariate analysis, compared to d4T/
3TC/NVP, starting ART with another NNRTI-containing regimen, with PI only or with a triple NRTI regimen was associated
with a higher risk of combination change (relative risk (RR) 1.6 (95% CI 1.64 – 1.96), p < 0.001, RR 3.39 (2.76 – 4.16) p < 0.001,
RR 6.37 (4.51 – 9.00), p < 0.001). Being on a second or a third combination regimen was also associated with a decreased rate
of ART change, compared with first ART combination (RR 0.82 (0.68 – 0.99), p = 0.035, RR 0.77 (0.61 – 0.97), p = 0.024). Sites
with fewer than 12 drugs used had an increased rate of treatment changes (1.31 (1.13 – 1.51), p < 0.001). Injecting drug users,
and other/unknown exposure was found to increase rate of treatment change (1.24 (1.00 – 1.54), p = 0.055). Percentages of
patients who stopped treatment due to adverse events were 31, 27 and 32 in 1st, 2nd and 3rd treatment combinations,
respectively.
Conclusion: Our study suggests that drug availability impacts on ART prescription patterns. Our data, reflecting real clinic use
in Asia, suggest that around half of all patients require second combination ART by 3 years after treatment initiation.
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Background
In South and South-East Asia the number of people living
with HIV/AIDS in 2005 was 7,800,000, the second high-
est in the world after Sub-Saharan Africa [1]. Combina-
tion antiretroviral treatments have been widely available
in Asia since 2003 [2].
The urgent need to provide antiretroviral therapy (ART)
on a large scale resulted in a growing number of patients
starting a simple, efficient, and standardized first line reg-
imen. First line regimens usually include 2 nucleoside
reverse transcriptase inhibitors (NRTI) and one non- nucl-
eoside reverse transcriptase inhibitors (NNRTI), and this
regimen can be co-formulated in a an easily administered
fixed dose combination of d4T, 3TC and nevirapine [3].
Previous analyses have confirmed the efficiency of this
approach [4-6].
Keeping the first line regimen as long as possible is con-
sidered essential. Adherence is of critical importance for
long term durability because of the low genetic barrier to
resistance for NNRTI-based regimens [7]. Experience from
Western cohorts however shows that very few patients stay
on a first regimen, with the median time of a first line reg-
imen 1.6 years in a US cohort [8]. Previous analyses from
the Australian HIV observational database (AHOD)
showed that patients remain on their first treatment for a
median 646 days (1.8 years) [9].
The range of drug options available in many Asian coun-
tries is not as wide as that available in developed coun-
tries. Moreover, the scale of epidemic implies that large
numbers of patients need alternative first line or second
line regimen. Reasons for switching are often related to
treatment-related toxicity and adherence problems, and
later in the course of the treatment, because of treatment
failure [10,11]. Monitoring ART use in Asia is important:
firstly, several countries in Asia have some of the highest
patient loads in the world [12]. Secondly, Asian countries
are very heterogeneous in terms of income access, pattern
of the HIV epidemic, and treatment programs. In this
paper, we explore the hypotheses that these differences
might have some effect on the outcomes, which differ
from that in Western cohorts. Assessing the durability of
ART regimens in Asia is imperative if we are to plan accu-
rately for long term ART procurement needs. Understand-
ing the pattern of antiretroviral treatment in different
regions of the world to tailor adequate second line and
salvage treatment strategies is thus warranted.
The aim of this study is to explore the rates and predictors
of the change of combination antiretroviral therapy in
clinical practice of treatment naïve patients in the TREAT
Asia HIV Observation Database (TAHOD) with a specific
emphasis to differences in drug availability across the
region.
Methods
Data from TAHOD, the Therapeutics Research, Education,
and AIDS training in Asia (TREAT Asia) HIV observational
database, were used in this study. TREAT Asia is a cooper-
ative network of clinicians throughout Asia and the Pacific
that aims to expand the capacity for broader introduction
of HIV/AIDS in the region. TAHOD is the first collabora-
tive study by the TREAT Asia network. TAHOD involves
15 clinical sites in the Asia and the Pacific region. Criteria
for site selection were based on the ability to contribute
data in an appropriate format within the initial 3-year
period. We also tried to retain sites so as to represent
countries across the region. Available funding limited
patient recruitment to 200 patients per site. With limited
resources, it was thought that recruiting an entirely repre-
sentative sample of all patients attending a site was unach-
ievable. Instead, the emphasis was placed on recruiting
patients who were thought likely to remain in follow-up.
Each site identified patients with regular clinic follow-up
and then recruited a consecutive sample of such patients,
aiming to recruit patients receiving and not receiving
antiretroviral treatment at the time of recruitment.
Although this recruitment approach does not provide
patient samples that are entirely representative of patients
attending a site, the expected good follow-up rates ensure
that robust analyses can be made regarding the natural
history of HIV disease on and off antiretroviral treatment.
Ethics approved was obtained from the University of New
South Wales and a local committee for each site. Since
data were entirely observational, informed consent was
not obtained, unless specifically requested by sites local
ethics committee. More detail of TAHOD methods is
described elsewhere [6,13].
Data collected in TAHOD included 1) demographic data,
2) stage of disease (CD4 and CD8 cell count, HIV-RNA
test date and result, AIDS-defining illness [defined accord-
ing to 1993 Center for Disease Control and Prevention
(CDC) revision of the AIDS case definition], and date and
cause of death); and 3) treatment. All data were entirely
observational, with tests or interventions performed
according to clinical guidelines at each clinical site. Data
were combined via standardized formats in Microsoft
Excel and transferred electronically (compressed with
password-protection) to the National Centre in HIV Epi-
demiology and Clinical Research (NCHECR) for central
aggregation and analysis. Ethical approval for the study
was obtained from the University of New South Wales
Ethics committee and from local Ethics committees.
TAHOD patients commencing their first ART with 3 or
more antiretroviral drugs and who had baseline and atAIDS Research and Therapy 2007, 4:18 http://www.aidsrestherapy.com/content/4/1/18
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least 1 follow-up visit were included in this study. Retro-
spective and prospective data with follow-up until Sep-
tember 2005 were included in this analysis.
Combination treatment change was defined as any
change in ART excluding dosage change. Any start or stop
of an individual antiretroviral drug was considered to be a
treatment change. An interruption of a drug of less than
14 days was not considered to be a treatment change.
Patients who died were assumed to stop treatment on that
day, and this was counted as a treatment change.
Country income category was classified according to the
World Bank criterion for classifying economies. Four
groups divided by 2005 gross national income (GNI) per
capita are identified: low income country ($875 or less),
lower-middle income ($876 – $3,465), upper middle
income ($3,466 – $10,725) and high income country
($10,726 or more) [14].
Availability of antiretroviral treatment at each site was
expressed as the number of drugs reported to have ever
been used by TAHOD patients seen at that site.
Reasons for stopping treatment are collected in TAHOD
by physician report at the time of stopping an individual
drug. The physician reports the major reason believed to
be underlying the reason for stopping a drug. Reasons
include treatment failure, clinical progression/hospitalisa-
tion, patient decision/request, compliance difficulties,
drug interaction, adverse event and other.
Statistical analysis
Rate of changing antiretroviral therapy was calculated as
the number of events over the person-years follow-up. The
time to change for the first, second and third combination
was estimated using Kaplan-Meier method. Factors associ-
ated with the rate of change were assessed using random-
effect Poisson regression methods that allow for multiple
treatment changes (events) within individual patients.
Factors included were, age at initiation of combination
treatment, sex, exposure category (heterosexual, homo-
sexual, IDU and other exposures or unknown), CD4 and
viral load at initiation of combination treatment, previous
AIDS defining illness, calendar year, number of combina-
tion, type of treatment (d4T/3TC/NVP; combinations of
ART with NNRTI no PI, other than d4T/3TC/NVP; combi-
nations of ART with PI no NRTI; and NNRTI only), coun-
try income category [14] and number of antiretroviral
treatment availability in the country. Variables with a p-
value less than or equal 0.10 were considered for inclu-
sion in multivariate models. Multivariate models were
built using forward stepwise techniques. Variables
included in the final multivariate model were assessed for
interactions. Overall survival was compared between
groups using Cox regression. Time to stopping the first
regimen due to toxicities and treatment failures was sum-
marised using a cumulative incidence plot, which allows
for the competing risk nature of the data[15,16]. Statisti-
cal significance was taken as a 2-sided p-value of less than
0.05. All the analyses were performed using STATA, soft-
ware, version 8.2 [17]
Results
Patient's characteristics
From September 2003 to September 2005, 2979 patients
were recruited to TAHOD, including 2345 patients who
commenced ART.
Details of patient's characteristic are shown in table 1. The
majority of patients were male (71%). The mean age at
the first treatment was 36.8 years. The main reported
transmission route was heterosexual contact (72%). Dis-
tribution of income category among sites participating to
TAHOD was well balanced, with 47% of TAHOD partici-
pating sites from lower middle income countries, 24%
from a low income and 29% from upper middle and high
income country according to World Bank report. Twenty
six percent of patients were recorded as having a previous
AIDS defining illness prior to treatment initiation. 80% of
patients were started on an NNRTI based regimen, among
whom 37% initiated treatment with a combination of
d4T/3TC/NVP. The majority of patients who started with
3 or more drugs including NNRTI, no PI (other than d4T/
3TC/NVP) were on 3TC/AZT/EFV (238/791) and 3TC/
d4T/EFVI (165/791). The median [range] number of
drugs prescribed at least once in each site was 12 [6-16].
The median number [range] of NRTI, NNRTI and PI were
5 [3-6], 2 [2,2] and 5 [1-8], respectively (Table 1).
Individual patient data on ART funding are not collected
in TAHOD. However, a site survey showed that all 15 sites
that responded to the survey were able to subsidise the
first line regimen. Eight sites were able to provide free first
line ART to TAHOD patients, while the remaining 7 sites
could only partially support the cost of ART for the first
line regimen. Only 9 sites out of 15 were able to subsidise
a second line regimen, of whom 5 could provide free ART.
Rate of treatment change
Out of 2345 patients who started ART, 1846 patients
started first treatment with 3 or more drugs in combina-
tion. The median follow-up of this cohort was 2.4 years.
The overall rate of combination antiretroviral treatment
change after the first combination treatment was 29 per
100 person-years. Rates for second and third change were
41 per 100 person-years in both changes.
The median duration of first, second and third treatments
are shown in Figure 1. The patients remained on their firstAIDS Research and Therapy 2007, 4:18 http://www.aidsrestherapy.com/content/4/1/18
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combination for a median of 3.2 (1.2 – 6.3) years. Out of
the 1846 patients, 719 patients changed their first treat-
ment and 6% of subsequent treatment regimen included
a PI. 596 out of 719 (83%) started a second regimen with
a median duration of 1.4 (0.3 – 3.9) years. 343 (58%)
patients started a third regimen with a median duration of
1.5 (0.7 – 3.6) years.
45 patients ceased their first regimen due to treatment fail-
ure, with a median treatment duration of 1.2 years. 4, 18
and 19 patients ceased their first regimen due to treatment
failure while on d4T/3TC/NVP, other NNRTI based regi-
men, and PI based regimen respectively, with median
durations in these patients of 1.6, 1.2 and 1.2 years respec-
tively. The cumulative incidence of changing the first reg-
imen due to toxicities or treatment failure are shown in
Figure 2.
The main reasons reported for stopping first, second and
third treatment were adverse events (Table 2). Lipoatro-
phy was the most common side effect leading to treat-
ment change in the first treatment combination. Anaemia
and rash were the most common reason accounting for
treatment change in the second and third combinations
(Table 3). Toxicities leading to ceasing the first treatment
regimen is broken down before and after 6 months in
Table 4. Lipoatrophy was more common after 6 months
with d4T/3TV/NVP treatment, while rash was more com-
mon before 6 months. Anaemia was found only in the
first 6 months of treatment (10/129) and none was found
in d4T/3TC/NVP regimen.
Combination therapy characteristic at switch
In the participating sites from low income and lower-mid-
dle income countries (n = 10/15 sites), 14% of the
Duration of first, second and third combination treatment Figure 1
Duration of first, second and third combination treatment.
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Table 1: Baseline characteristics at first treatment 
combination (N = 1,846)
Characteristics
Age, years mean (SD) 36.9 (10)
Gender, n (%)
- Male 1,324 (71.7)
- Female 520 (28.2)
- Transgender 2 (0.1)
Ethnicity, n (%)
- Chinese 567 (31)
- Indian 375 (20)
- Thai 502 (27)
- Others 402 (22)
Exposure, n(%)
- Heterosexual 1,333 (72)
- IDU +others +unknown 192 (11)
- Homosexual 321 (17)
Income, n (%)
- Low income 451 (24)
- Lower middle income 859 (47)
- Upper middle and high income 536 (29)
CD4 cells/µL at baseline, n (%)
- < 50 432 (23)
- 51 – 100 215 (11)
- 101 – 200 309 (17)
- > 200 232 (13)
- Missing 658 (36)
HIVRNA at baseline, n (%)
- < 100,000 210 (11)
- > 100,000 256 (14)
- Missing 1380 (75)
Previous AIDS, n(%)
- No previous ADI 1363 (74)
- Previous ADI 483 (26)
First treatment combination, n(%)
- d4T/3TC/NVP 676 (37)
- 3 or more ART with NNRTI, no PI (other than 
d4T/3TC/NVP)
791 (43)
- 3TC/AZT/EFV 238
- 3TC/d4T/EFV 165
- 3TC/AZT/NVP 161
- ddI/d4T/EFV 82
- ddI/d4T/NVP 68
- ddI/AZT/EFV 24
- ddI/3TC/EFV 16
- others 37
- 3 or more ART, with PI, no NNRTI 344 (19)
- Indinavir 124
- Lopinavir 90
- Nelfinavir 49
- Saquinavir 33
- Atazanavir 20
- others 28
- 3 or more ART, NRTI only 17 (1)
- ABC/3TC/AZT 8
- ddI/3TC/AZT 6
- others 3
Others 18 (1)
Median (IQR) number of drugs 12 (6 – 16)AIDS Research and Therapy 2007, 4:18 http://www.aidsrestherapy.com/content/4/1/18
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patients had data available on CD4 T cell count within 3
months before the occurrence of the treatment change.
For patients for whom CD4 T cell count was available, the
latest CD4 cell count before the switch to the second regi-
men showed that 9% of patients had CD4 T cell count
below 50, 7% had CD4 T cell counts of 51–100 and 21%
from 101–200. Similarly in low and lower-middle income
countries, HIV-RNA was measured in only 26% of the
patients overall before a switch to a second regimen, and
in 21% of patients before the switch to third regimen,
indicating that these monitoring tests are not routinely
performed.
Predictors of rates of combination treatment change
Table 5 shows factors associated with rates of combina-
tion treatment change. In univariate analyses factors
related to rate ratios of combination treatment change
were; country income category (p = 0.002), drug class
combination at baseline (p < 0.001), number of combina-
tions (p < 0.001), calendar year (p = 0.002) and number
of drugs available (p = 0.009).
In the multivariate model, the type of regimen used at
treatment initiation significantly predicted the rate ratios
of subsequent changes (with NNRTI and no PI; RR 1.64
(1.38 – 1.96) p < 0.001, with PI no NNRTI; RR 3.39 (2.76
– 4.16) p < 0.001, NRTI only; RR 6.37. (4.51 – 9.00) p <
0.001, reference regimen is d4T/3TC/NVP). Moreover,
being on a second or a third combination regimen was
associated with a reduced rate ratio of change in ART, as
compared with being on a first prescribed combination
therapy (second RR 0.82 (0.68 – 0.99) p = 0.039, third RR
0.77 (0.61 – 0.97), p = 0.024). Sites with fewer than 12
drugs available had an increased rate of treatment changes
(1.31 (1.13 – 1.51), p < 0.001). This increased rate of
treatment change was largely driven by the large number
of drug cessation, with 119 of 752 treatment changes due
to simply stopping in sites with fewer than 12 drugs used,
compared with 72 of 739 changes in sites with 12 or more
drugs used. Exposure category was also found to be asso-
ciated with rates of treatment changes. In particular,
injecting drug users, and other/unknown exposure was
found to have an increased rate of treatment change (1.24
(1.00 – 1.54), p = 0.055). Rate ratios from non-statisti-
cally significant factors considered for inclusion in multi-
variate models are also presented in Table 6 adjusted for
the statistically significant variables included in the multi-
variate model. The key variables included in the final mul-
tivariate model were also assessed for interaction effects,
but no statistically significant interaction effects were
found (data not shown).
Survival by income category
There were 34 deaths in patients included in these analy-
ses, an overall mortality rate of 6.6 per 1,000 person years.
Compared to low income countries, survival in high
Table 3: Main adverse events for 1st, 2ndand 3rd
Treatment, n(%)
Adverse events 1 (n = 129) 2 (n = 50) 3 (n = 41)
Lipoatrophy 26 (20) 11 (22) 5 (12)
Rash 13 (10) 0 (0) 11 (27)
Anaemia 10 (8) 10 (20) 4 (10)
Neuropathy 5 (4) 4 (8) 1 (2)
Metabolic 
disturbance
6 (6) 0 (0) 0 (0)
Cumulative incident of toxicity and treatment failure in the  first treatment Figure 2
Cumulative incident of toxicity and treatment failure in the 
first treatment. x axis is "years". Y axis is "cumulative inci-
dence". green line represents toxicity failure. red line repre-
sents treatment failure [see Figure 2]
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Table 2: Reasons for stopped 1st, 2nd and 3rd treatments
Treatments, n(%)
Reason 1 (n = 413) 2 (n = 188) 3 (n = 130)
Adverse events 129 (31) 50 (27) 41 (32)
Others 116 (28) 65 (35) 36 (28)
Treatment 
failure
45 (11) 27 (14) 21 (16)
Patient 
decision/
request
75 (18) 22 (12) 19 (15)
Compliance 
difficulties
29 (7) 14 (7) 7 (5)
Clinical 
progression/
hospitalisation
11 (3) 9 (5) 1 (0.7)
Drug 
interaction
8 (2) 1 (0.5) 5 (4)AIDS Research and Therapy 2007, 4:18 http://www.aidsrestherapy.com/content/4/1/18
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income countries was not statistically significantly raised,
(hazard ratio = 1.6, (95% CI; 0.5 – 5.3), p = 0.414).
Discussion
We analysed the pattern of ART changes in various Asian
sites participating in TAHOD. The patients remained on
their first combination for a median of 3.2 (1.2 – 11.7)
years. The overall rate of combination treatment change in
this cohort was 29 per 100-person year. We observed sig-
nificantly higher treatment duration in sites located in low
income countries as compared with sites from higher
income countries (p < 0.001).
These differences could have been expected from previous
report generated from data in the US and Australia's
cohorts. Chen et al showed that the median duration of a
first combination did not exceed 1.6 years [8]. Pallela et al
in the HIV Outpatient Study (HOPS) in the USA have
shown even shorter duration with only 11.8 months spent
on the first prescribed regimen[18]. The Australian HIV
observational database used the same criteria as ours to
define rate of changes and has the same number of years
of follow-up (2.3 years) [8,9,18]. The rate of combination
antiretroviral treatment change in The Australian HIV
Observation Database (AHOD) was 0.45 combinations
per year, which is higher than our result of 0.29 combina-
tions per year [9]. There are however substantial differ-
ences between the 2 study populations. In TAHOD about
50% of patients started their first treatment with CD4 less
than 200 cells/µL compared with 23% in AHOD. We
found 26% of TAHOD reported having a previous AIDS
defining illness while only 11% reported in AHOD. Thus,
our data suggest that despite advanced disease, patients in
TAHOD tolerate well the first prescribed regimen and
change at a much slower rate than in AHOD.
We also found that the rate of treatment change in the sec-
ond and third regimens were at a slower rate than the first
treatment (relative rates of 0.81 and 0.70 respectively).
This contrasts with results from AHOD which found that
the rate of change did not change statistically significantly
in second and third combinations[9]. This may also be a
reflection on how treatment availability impact on the
treatment strategies. Even though the results from both
Western cohorts showed shorter time on first treatment, it
should be noted that these findings were based on data
from an earlier period when there were fewer antiretrovi-
ral treatments available, a greater proportion of patients
previously treated with mono and double therapy, and
arguably that physicians were less experienced, factors
that could affect rates of treatment change.
Our results tend to illustrate that in the context of limited
resources, where the first regimen appears to be by far the
cheapest option, clinicians might be reluctant to switch
even in the context of true virological failure to alternative
more expensive options if the patient is not clinically
symptomatic, thereby running the risk that they jeopard-
ize the chances of finding a successful regimen later on.
This risk, however, is only present if the reason for switch-
ing is virological failure. It is also the case that HIV viral
load testing is often not routinely performed in low
income countries, meaning that true virological failure
may not be detected. Alternatively, if second or third line
regimens are relatively unaffordable or not available, this
may influence decisions to even perform HIV viral load
testing. This could to some extent explain the low rate of
treatment changes in TAHOD as compared to AHOD,
despite patients at more severe disease stages. Indeed,
when looking for predictors of treatment changes, income
category was significantly associated only in the univariate
Table 4: Toxicities reported as reason for first treatment change before and after 6 months, by treatment (n = 129)
Treatment (%)
Reasons d4T/3TC/NVP with NNRTI, no PI with PI
≤ 6 mths > 6 mths ≤ 6 mths > 6 mths ≤ 6 mths > 6 mths
Others 6 (5) 5 (4) 9 (7) 15 4 (3) 6 (5)
Lipoatrophy 0 (0) 19 (15) 0 (0) 6 0 (0) 1 (0.8)
Rash 7 (5) 1 (0.8) 2 (1.6) 0 (0) 3 (2) 0 (0)
Anemia 0 (0) 0 (0) 7 (5) 0 (0) 2 (1.6) 0 (0)
Hepatitis 5 (4) 2 (1.6) 1 (0.8) 0 (0) 0 (0) 0 (0)
GI symptoms 1 (0.8) 0 (0) 2 (1.6) 0 (0) 4 (3) 0 (0)
Lactic acidosis and 
hyperlactatemia
0 (0) 3 (2) 0 (0) 2 1 (0.8) 1 (0.8)
Metabolic 
Disturbance
0 (0) 1 (0.8) 0 (0) 3 0 (0) 1 (0.8)
Peripheral 
neuropathy
1 (0.8) 0 (0) 1 (0.8) 3 0 (0) 0 (0)AIDS Research and Therapy 2007, 4:18 http://www.aidsrestherapy.com/content/4/1/18
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model. Beside the effect of different treatment options
being different from country to country, we also analysed
the effect of the type of first prescribed regimen in our
study. Patients who started with d4T/3TC/NVP stopped or
changed their treatments at a slower rate than patients
who started their treatment with other regimens. This con-
firms previously published report from TAHOD on a
smaller sample of patient (n = 404) [11]. This also could
be linked to the fact that this combination is the cheapest
available. It could also be related to TAHOD being rela-
tively young and the follow-up time still relatively short,
so that long-term, chronic d4T related mitochondrial tox-
icity will be seen more frequently with longer follow-up.
Further results from TAHOD have shown that patients
who were on a d4T based regimen were more likely to
cease treatment than patients who were on an AZT based
regimen after greater than 9 months treatment [19].
1,846 patients started an NNRTI based regimen as first
combination. Of the 719 who stopped or started any
drug, 6% switched to a PI based regimen. Moreover, only
a minority of the switches have been triggered by the usual
surrogate markers used in Western countries, such as CD4
and VL. As already shown in TAHOD [11], this analysis
Table 5: Factors associated with rates of combination antiretroviral treatment changes
Univariate1
N Follow Up (years) # events Rate/follow-up year RR (95% CI) p
Overall 1846 5121.3 1491 0.29
Age(per 10 years) 1.04 (0.98 – 1.12) 0.220
Sex
Male 1324 3734 1081 0.29 1.00 ...
Female 520 1384 408 0.29 1.01 (0.87 – 1.17) 0.905
Exposure 0.004
Heterosexual 1333 3770 1052 0.28 1.00 ...
IDU + others + unknown 192 433 171 0.40 1.43 (1.16 – 1.78) 0.615
Homosexual 321 918 268 0.29 1.09 (0.91 – 1.30) 0.348
Income category 0.0042
Low income 451 1079 263 0.24 1.00 ...
Lower middle income 859 2319 669 0.29 1.14 (0.95 – 1.36) 0.159
Upper middle high income 536 1723 559 0.35 1.31 (1.09 – 1.58) 0.005
Previous AIDS
No 1363 4569 1331 0.29 1.00 ...
Yes 483 552 160 0.29 1.09 (0.94 – 1.27) 0.255
CD4 0.3172
< 50 432 1147 335 0.29 1.00 ...
51 – 100 213 544 145 0.27 0.93 (0.72 – 1.20) 0.549
101 – 200 309 821 224 0.27 0.98 (0.79 – 1.22) 0.884
- > 200 232 725 221 0.30 1.14 (0.90 – 1.28) 0.267
Missing 660 1885 566 0.30
HIV-RNA
≤ 100,000 210 700 261 0.37 1.00 ...
> 100,000 256 752 234 0.31 0.84 (0.66 – 1.07) 0.169
Missing 1380 3669 996 0.27
Drug class combination <0.001
d4T/3TC/NVP 676 1497 219 0.15 1.00 ...
with NNRTI, no PI 791 2392 576 0.24 1.59 (1.35 – 1.88) <0.001
with PI, no NNRTI 344 926 390 0.42 2.88 (2.40 – 3.45) <0.001
NRTI only 17 102 72 0.71 5.38 (3.94 – 7.35) <0.001
Others 18 205 234 1.14
Combination3 <0.0013
First 1846 3360 764 0.23 1.00 ...
Second 719 908 376 0.41 1.22 (1.03 – 1.44) 0.023
Third + 692 853 351 0.41 0.72 (0.58 – 0.89) 0.003
Calendar year
≥ 2003 808 3907 1053 0.27 1.00 ...
≤ 1999 – 2002 1038 1214 438 0.36 1.23 (1.10 – 1.40) 0.001
Number of drugs available4
> 12 922 2742 739 0.27 1.00 ...
≤ 12 924 2379 752 0.32 1.19 (1.04 – 1.36) 0.009AIDS Research and Therapy 2007, 4:18 http://www.aidsrestherapy.com/content/4/1/18
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confirms the hypothesis that most of the switches are due
to toxicity or tolerance issues rather than related to treat-
ment failure at least in the short or medium term. It may
also be that clinicians are reluctant to put the patients on
a second regimen when limited treatment options are
available. The low rates of treatment changes on second
and third combinations may reflect scarcity of affordable
or available salvage options rather than durability of regi-
mens. Even though income category was not statistically
significant in the multivariate models, it is worth noting
that rates of changing treatment were slower in low
income countries in univariate models, and this became
non-significant on adjustment for type of ART regimen.
This seemingly high threshold to switch therapy among
clinically stable patients probably reflects persisting with
cheaper, generic treatment regimens in patients who are
either failing virologically or do not have HIV viral load
tests available, and raises issue regarding development of
drug resistance. TAHOD plans to address these issues in
future analyses based on studies of drug resistance. We
were unable to separate individual patients who received
free ART from those who had to pay for their own treat-
ments. We had, however, site details about free access to
ART and the majority of patients were able to access to free
ART. This might not be the real practice in Asian countries
as these sites are mainly academic sites, and patients
might also participate in clinical trials.
There were some limitations in this study. First, we used
retrospective and prospective data. This limitation led to
some gaps in information about why patients stopped
their treatment which might be clinically relevant. Based
on prospective data, we found that 31% of patients
stopped their treatment because of adverse events in the
first treatment, 27% and 32% in the second and third
treatment combination, respectively. Lipoatrophy is the
major reason for patients to stop their treatment. Second,
TAHOD patients might not be completely representative
of HIV-infected patients in Asia-pacific region: only
patients with a good follow-up (according to the physi-
cian's opinion) are recruited. Furthermore TAHOD sites
are generally located at academic centres in the region.
Care should be taken in extrapolating our results to all
patients treated in the Asia-Pacific region. Third, because
individual patient data were not available, the country
income category was measured at an ecological level using
the World Bank classification. This might not truly repre-
sent individual patient's income in some sites. In particu-
lar, it is likely that patients from a site in a nominal low
income country are of higher income status than is typi-
cal, or that HIV patients from a nominal high income
country are from a lower income status within that coun-
try. It may be that patients seen at nominal low income
sites have a greater range of treatment options than would
be typical, especially since our sites are mainly from aca-
demic centres. Similarly, the number of drugs available is
an ecological variable based on the total number of drugs
that had been used in TAHOD patients at a given site. Not
all these drugs may be available to all TAHOD patients,
and so may overestimate drug availability. Fourth, we col-
lect the main reason as reported by the physician for stop-
ping treatment, but reasons for stopping are often
interrelated. For example, clinical progression and treat-
ment failure are often related. Patient request may reflect
financial difficulty or toxicity. Reasons for stopping treat-
ment cannot be further delineated in TAHOD, and should
be interpreted cautiously.
Our study found lower rates of antiretroviral treatment
change than in developed country cohorts. Within
TAHOD, higher income countries had a greater rate of
Table 6: Multivariate model for factors associated with rates of 
combination antiretroviral treatment changes
Multivariate5
RR (95% CI) p
Drug class 
combination
<0.001
d4T/3TC/NVP 1.00 ...
with NNRTI, no PI 1.64 (1.38 – 1.96) <0.001
with PI, no NNRTI 3.39 (2.76 – 4.16) <0.001
NRTI only 6.37 (4.51 – 9.00) <0.001
Others
Combination3 0.0193
First 1.00 ...
Second 0.82 (0.68 – 0.99) 0.035
Third + 0.77 (0.61 – 0.97) 0.024
Number of drugs 
available5
> 12 1.00 ...
≤ 12 1.31 (1.13 – 1.51) < 0.001
Exposure 0.047
Heterosexual 1.00 ...
IDU + others + 
unknown
1.24 (1.00 – 1.54) 0.055
Homosexual 0.88 (0.73 – 1.07) 0.209
Income category 0.824
Low income 1.00 ...
Lower middle Income 1.25 (0.98 – 1.56) 0.068
Upper middle high 
income
1.06 (0.85 – 1.33) 0.581
Calendar year
≥ 2003 1.00 ...
≤ 1999 – 2002 1.13 (0.98 – 1.30) 0.086
1 Estimated univariate Relative rates (RR) from random effects 
Poisson model may not equal ratio of crude rates
2 p from test for trend
3 Second and third combinations included patients who were not on 
combination treatment
4 Total number of drugs that have been used in TAHOD patients at 
the site where patients were receiving care
5 Variables included in the final multivariate model are presented in 
bold. All other non-significant variables are also presented adjusted 
for the variables included in the final multivariate model.AIDS Research and Therapy 2007, 4:18 http://www.aidsrestherapy.com/content/4/1/18
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antiretroviral treatment change than low income coun-
tries, although this difference disappeared on adjustment
for other treatment variables. A lower total number of
drugs available was also associated with a greater rate of
treatment change, and in particular more treatment cessa-
tions rather than switches. Taken together, this suggests
that drug availability does impact the strategies used by
clinicians to change the antiretroviral regimen. A recent
report from the Global Fund has shown that any increase
of alternative first line and second line drugs will more
than double the budget allocated to ART drugs in some
programs. Forecasting the need in terms of treatment reg-
imen in a region with a high patient load is therefore a key
issue. Resources should be made available for patients to
have access to a wider range of treatment options.
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